Aadi Bioscience (NASDAQ:AADI) Trading Up 3.7%

Aadi Bioscience, Inc. (NASDAQ:AADIGet Free Report)’s stock price was up 3.7% during trading on Friday . The stock traded as high as $1.71 and last traded at $1.69. Approximately 291,657 shares changed hands during mid-day trading, a decline of 4% from the average daily volume of 302,314 shares. The stock had previously closed at $1.63.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Aadi Bioscience in a research report on Tuesday, May 14th.

Get Our Latest Analysis on Aadi Bioscience

Aadi Bioscience Stock Performance

The company has a market capitalization of $41.49 million, a PE ratio of -0.66 and a beta of 0.66. The business’s 50-day moving average is $1.82 and its 200-day moving average is $2.09.

Aadi Bioscience (NASDAQ:AADIGet Free Report) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.02). Aadi Bioscience had a negative net margin of 288.72% and a negative return on equity of 61.83%. The business had revenue of $5.35 million for the quarter, compared to analysts’ expectations of $6.41 million. Analysts expect that Aadi Bioscience, Inc. will post -2.54 EPS for the current year.

Insider Activity at Aadi Bioscience

In related news, Chairman Neil Desai sold 17,772 shares of Aadi Bioscience stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $2.31, for a total transaction of $41,053.32. Following the completion of the transaction, the chairman now directly owns 1,393,771 shares of the company’s stock, valued at approximately $3,219,611.01. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 37.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Aadi Bioscience

An institutional investor recently bought a new position in Aadi Bioscience stock. Decheng Capital LLC bought a new stake in shares of Aadi Bioscience, Inc. (NASDAQ:AADIFree Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 526,329 shares of the company’s stock, valued at approximately $1,063,000. Aadi Bioscience comprises 0.3% of Decheng Capital LLC’s investment portfolio, making the stock its 22nd largest holding. Decheng Capital LLC owned approximately 2.15% of Aadi Bioscience at the end of the most recent quarter. 52.08% of the stock is currently owned by institutional investors and hedge funds.

Aadi Bioscience Company Profile

(Get Free Report)

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.

Featured Articles

Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.